{
    "nctId": "NCT04115306",
    "briefTitle": "Phase 1/1b/2 Study of Oral PMD-026 in Patients with Metastatic Breast Cancer",
    "officialTitle": "Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 As a Single Agent and in Combination in Patients with Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "Safety and tolerability of PMD-026 in combination with fulvestrant in patients with HR+/HER2- previously treated breast cancer",
    "eligibilityCriteria": "Inclusion Criteria, Combination with fulvestrant (Part 3):\n\n* Available archival or FFPE\n* RSK2 positive (\u226575% nuclear staining with \u22652+ in staining intensity) as assessed by central lab from available archival or fresh tumor tissue (FFPE).\n* Histologically or cytologically diagnosed HR+, HER2- defined as both\n\n  * \\>1% expression of ER and/or PgR receptor\n  * \u2264 1+ by IHC for HER2, or FISH negative. If 2+ by IHC for HER2 combined with FISH negative\n* Diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amendable to resection or radiation with curative intent or metastatic disease not amendable to curative therapy\n* Must be appropriate candidates for endocrine therapy\n* Previously received at least 1 line of endocrine therapy for MBC or had recurrence while on adjuvant endocrine therapy for locally advanced breast cancer\n* Discontinued endocrine therapy at least 15 days prior to first dose of PMD-026\n* At least 1 measurable target lesion as defined by RECIST v1.1\n* Progression on or after treatment with a CDK4/6 inhibitor in combination with endocrine therapy inhibitor in the locally advanced or metastatic setting\n* Has not received fulvestrant in the locally advanced or metastatic setting. Note: If prior to study entry, a patient initiates fulvestrant in combination with targeted therapy and becomes intolerant of the targeted therapy before progression, that patient may enroll if PMD-026 is initiated within 48 days of start of fulvestrant and no missed doses of fulvestrant occurred.\n* Not eligible for an AKT or PI3K inhibitor\n* Adequate hematologic, hepatic, and renal function as assessed by laboratory parameters\n* Toxicity related to prior therapy resolved to at least Grade 1 (alopecia excepted) or to at least Grade 2 with prior approval of the Medical Monitor\n\nExclusion Criteria, Combination with fulvestrant (Part 3):\n\n* \u226414 days from prior chemotherapy, biological or investigational therapy\n* Prior fulvestrant in the locally advanced or metastatic setting\n* Presence of visceral crisis or uncontrolled visceral disease for which chemotherapy would be indicated\n* Central nervous system metastases, unless appropriately treated and neurologically stable\n* History of leptomeningeal metastases\n* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* Known hepatitis B or hepatitis C infection\n* Known HIV-positive with CD4+ cell counts \\<350 cells/\u03bcL\n* Known HIV-positive with a history of an AIDS-defining opportunistic infection\n* History of clinically significant cardiovascular abnormalities, including QTcF interval \\>460 msec (using Fridericia's formula)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}